Article

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

University of Wisconsin, 600 Highland Ave., Rm. H6/563 CSC, Madison, WI 53792-5132, USA.
Neurology (Impact Factor: 8.3). 11/2004; 63(8):1364-70. DOI: 10.1212/01.WNL.0000142042.50528.2F
Source: PubMed

ABSTRACT Patients with ALS commonly exhibit pseudobulbar affect.
The authors conducted a multicenter, randomized, double-blind, controlled, parallel, three-arm study to test a defined combination of dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) (AVP-923) for the treatment of pseudobulbar affect in ALS. Q inhibits the rapid first-pass metabolism of DM. The effects of AVP-923 (30 mg of DM plus 30 mg of Q) given twice daily for 28 days were compared with those of its components. Patients were evaluated on days 1, 15, and 29. The primary efficacy variable was the change from baseline in the Center for Neurologic Study Lability Scale (CNS-LS) score. Secondary efficacy variables were laughing/crying episode rates and changes in Visual Analog Scales for Quality of Life (QOL) and Relationships (QOR). Efficacy was evaluated in intention-to-treat subjects who were not poor metabolizers of DM (n = 65 for AVP-923, n = 30 for DM, and n = 34 for Q). Safety was assessed in all randomized subjects (n = 140).
AVP-923 patients experienced 3.3-point greater improvements in CNS-LS than DM patients (p = 0.001) and 3.7-point greater improvements than Q patients (p < 0.001). AVP-923 patients exhibited lower overall episode rates, improved QOL scores, and improved QOR scores (p < 0.01 for all endpoints). Adverse effects were mostly mild or moderate; treatment-related discontinuation was 24% for AVP-923, 6% for DM, and 8% for Q.
AVP-923 palliates pseudobulbar affect in ALS. Overall benefits of treatment are reflected in fewer episodes of crying and laughing and improvements in overall quality of life and quality of relationships.

0 Bookmarks
 · 
102 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pseudobulbar affect (PBA) is a common manifestation of brain pathology associated with many neurological diseases, including amyotrophic lateral sclerosis, Alzheimer's disease, stroke, multiple sclerosis, Parkinson's disease, and traumatic brain injury. PBA is defined by involuntary and uncontrollable expressed emotion that is exaggerated and inappropriate, and also incongruent with the underlying emotional state. Dextromethorphan/quinidine (DM/Q) is a combination product indicated for the treatment of PBA. The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite. Three published efficacy and safety studies support the use of DM/Q in the treatment of PBA; significant effects were seen on the primary end point, the Center for Neurologic Study-Lability Scale, as well as secondary efficacy end points and quality of life. While concentration-effect relationships appear relatively weak for efficacy parameters, concentrations of DM/Q may have an impact on safety. Some special safety concerns exist with DM/Q, primarily because of the drug interaction and QT prolongation potential of the quinidine component. However, because concentrations of dextrorphan (which is responsible for many of the parent drug's side effects) and quinidine are lower than those observed in clinical practice with these drugs administered alone, some of the perceived safety issues may not be as relevant with this low dose combination product. However, since patients with PBA have a variety of other medical problems and are on numerous other medications, they may not tolerate DM/Q adverse effects, or may be at risk for drug interactions. Some caution is warranted when initiating DM/Q treatment, particularly in patients with underlying risk factors for torsade de pointes and in those receiving medications that may interact with DM/Q.
    Neuropsychiatric Disease and Treatment 01/2014; 10:1161-74. DOI:10.2147/NDT.S30713 · 2.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tirasemtiv is a fast skeletal muscle activator that increases the sensitivity of the sarcomere to calcium, increasing the efficiency of muscle contraction when the muscle is stimulated at submaximal contraction frequencies. A previous study showed single doses of tirasemtiv to be well tolerated and associated with potentially important improvements in a variety of functional outcomes. This study determined safety of tirasemtiv when given at doses up to 500 mg daily for three weeks. Tirasemtiv was given as a single daily dose up to 375 mg for two weeks, with and without concomitant riluzole. In a separate cohort, an ascending dose protocol evaluated a total dose of 500 mg daily given in two divided doses. Safety and tolerability were assessed, as well as measures of function, muscle strength and endurance. Results showed that tirasemtiv was well tolerated, with dizziness the most common adverse event. Tirasemtiv approximately doubled the serum concentration of riluzole. Trends were noted for improvement in ALSFRS-R, Maximum Minute Ventilation, and Nasal Inspiratory Pressure. In conclusion, tirasemtiv is well tolerated and can be given safely with a reduced dose of riluzole. Positive trends in multiple exploratory outcome measures support the further study of this agent in ALS.
    08/2013; 14(7-8). DOI:10.3109/21678421.2013.822517
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Cerebrovascular disease is a major public health problem and common cause of neuropsychiatric disorders in the medically ill. Vascular lesions in the Central Nervous System cause signifi cant morbidity, usually followed by severe cognitive dysfunctions which become an important risk factor for developing psychopathology during the course of cerebrovascular disorders. Objective: To describe neuropsychiatric disorders affecting people with stroke other than post-stroke depression, as this will be reviewed extensively elsewhere. Method: Review of medical literature. Conclusions: Research on the neurobiology of mental disorders based on vascular theories to explain the etiology and physiopathology of some mental disorders has not come up with consistent results linking structural and functional studies with clinical correlates of neuropsychiatric syndromes. Implicit mechanisms responsible for the blend between systemic disease, neurological disorders and psychiatry are still poorly understood by the scientifi c community responsible for the treatment of cerebrovascular patients. Most studies are limited to case reports and series in severely ill patients leaving out those patients with mild to moderate stroke. These subjects are known to be at risk for neuropsychiatric disorders involving movement and cognitive symptoms such as Parkinson’s, dementia and delirium.
    10/2007; 36:63-91.

Full-text (2 Sources)

Download
297 Downloads
Available from
Jun 4, 2014